About Telix Pharmaceuticals
Telix Pharmaceuticals is a company based in Melbourne (Australia) founded in 2015. It operates as a Professional Services. Telix Pharmaceuticals has completed 9 acquisitions, including ANMI, ARTMS and ATLAB Pharma. Telix Pharmaceuticals offers products and services including Illuccix® and Gozellix®. Telix Pharmaceuticals operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others.
- Headquarter Melbourne, Australia
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Telix Pharmaceuticals Limited
-
Annual Revenue
$485.14 M (USD)55.85as on Dec 31, 2024
-
Net Profit
$30.92 M (USD)857.95as on Dec 31, 2024
-
EBITDA
$55.87 M (USD)54.36as on Dec 31, 2024
-
Latest Funding Round
$25 M (USD), Post-IPO
Nov 02, 2020
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
ANMI
& 8 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Telix Pharmaceuticals
Telix Pharmaceuticals is a publicly listed company on the ASX with ticker symbol TLX in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Telix Pharmaceuticals
Telix Pharmaceuticals offers a comprehensive portfolio of products and services, including Illuccix® and Gozellix®.
Used for prostate cancer imaging in diagnostics.
Employed for prostate cancer imaging and diagnosis.
People of Telix Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Telix Pharmaceuticals
Investors in Telix Pharmaceuticals
Telix Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include China Grand Pharmaceutical and Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finished formulations and APIs are manufactured for therapeutic categories.
|
Locked | Locked | Locked |
Investor details for Telix Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Telix Pharmaceuticals
Telix Pharmaceuticals has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include ANMI, ARTMS and ATLAB Pharma.
Investment portfolio details for Telix Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular imaging products and services are developed.
|
Locked | Locked | 2018 | Locked | |
|
AI-driven clinical decision support for diagnosis and therapy planning
|
Locked | Locked | 2017 | Locked | |
|
CDMO focused on synthesis of APIs
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Telix Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Telix Pharmaceuticals
Detailed financials for Telix Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Telix Pharmaceuticals Comparisons
Peer comparison for Telix Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Telix Pharmaceuticals
Telix Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, ImaginAb, Mariana Oncology and AdvanCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| Locked | Locked | Locked |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
Detailed competitors of Telix Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Telix Pharmaceuticals
Complete news archive for Telix Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Telix Pharmaceuticals
Telix Pharmaceuticals was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Telix Pharmaceuticals is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Annual revenue of Telix Pharmaceuticals is $485.14M as on Dec 31, 2024.
Telix Pharmaceuticals is engaged in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, often referred to as theranostics. The companys extensive pipeline targets urologic oncology including prostate and kidney cancers, neuro-oncology such as glioma, musculoskeletal oncology like sarcoma, and bone marrow conditioning. Operations are supported by a robust global supply, manufacturing, and distribution network. Multiple clinical trials are conducted worldwide, with key products like Illuccix receiving regulatory approvals in various regions for prostate cancer imaging.
Telix Pharmaceuticals's top competitors include Advanced Accelerator Applications, ImaginAb and SOFIE.
Telix Pharmaceuticals offers Illuccix® and Gozellix®.
Yes, Telix Pharmaceuticals is publicly traded on ASX under the ticker symbol TLX.
Telix Pharmaceuticals has made 9 acquisitions, including ANMI, ARTMS, and ATLAB Pharma.
Telix Pharmaceuticals has 1 investor. Key investors include China Grand Pharmaceutical and Healthcare.
The ticker symbol of Telix Pharmaceuticals is TLX on ASX.